Mostrando 10 resultados de: 18
Filtros aplicados
Publisher
Pharmacogenomics Journal(4)
Pharmacogenomics(3)
Drug Metabolism and Personalized Therapy(2)
European Journal of Clinical Pharmacology(2)
British Journal of Clinical Pharmacology(1)
Área temáticas
Enfermedades(15)
Farmacología y terapéutica(10)
Medicina y salud(4)
Bioquímica(3)
Ginecología, obstetricia, pediatría, geriatría(3)
Objetivos de Desarrollo Sostenible
ODS 3: Salud y bienestar(18)
ODS 10: Reducción de las desigualdades(15)
ODS 17: Alianzas para lograr los objetivos(2)
ODS 12: Producción y consumo responsables(1)
Origen
scopus(18)
Clinical implementation of pharmacogenetics and personalized drug prescription based on e-health: The MedeA initiative
ArticleAbstract:Palabras claves:Autores:Adrián LLerena, Cobaleda J., de Andrés F., Mata-Martín C., Penãs-Lledó E.M., Pijierro A., Sánchez C.L.Fuentes:scopusAssociation between T102C and A-1438G polymorphisms in the serotonin receptor 2A (5-HT2A) gene and schizophrenia: Relevance for treatment with antipsychotic drugs
ArticleAbstract: Background: An involvement of serotonin receptor 2A (5-HT2A) in the aetiology of schizophrenia has bPalabras claves:A-1438G polymorphism, Risperidone, Schizophrenia, Seretonin 2A receptor, T102C polymorphismAutores:Adrián LLerena, Cáceres M.C., De la Rubia A., Dorado P., Penãs-Lledó E.M.Fuentes:scopusAntipsychotic drugs and QTc prolongation: The potential role of CYP2D6 genetic polymorphism
ReviewAbstract: Although the most common, and usually serious, side effects of first-generation (or typical) antipsyPalabras claves:Antipsychotic drugs, Cardiac side effects, CYP2D6, drug metabolism, QT interval lengthening, Torsades de pointes-type arrhythmiaAutores:Adrián LLerena, Berecz R., Dorado P., Penãs-Lledó E.M.Fuentes:scopusCYP2D6 polymorphism: Implications for antipsychotic drug response, schizophrenia and personality traits
ReviewAbstract: The CYP2D6 gene is highly polymorphic, causing absent (poor metabolizers), decreased, normal or incrPalabras claves:Adverse side effects, antipsychotics, CYP2D6, personality, pharmacogenetics, Pharmacogenomics, QTc, Schizophrenia, vulnerabilityAutores:Adrián LLerena, Dorado P., Penãs-Lledó E.M.Fuentes:scopusCYP2D6 variation, behaviour and psychopathology: Implications for pharmacogenomics-guided clinical trials
ArticleAbstract: Individual and population differences in polymorphic cytochrome P450 enzyme function have been knownPalabras claves:clinical trials, CYP2D6, endogenous compound metabolism, personality traits, pharmacogenetics, psychopathologyAutores:Adrián LLerena, Penãs-Lledó E.M.Fuentes:scopusAripiprazole-induced parkinsonism and its association with dopamine and serotonin receptor polymorphisms
OtherAbstract:Palabras claves:Autores:Adrián LLerena, Dorado P., López-Torres E., Penãs-Lledó E.M., Salomón J., Vicario F.Fuentes:scopusEffect of CYP2D6 and CYP2C9 genotypes on fluoxetine and norfluoxetine plasma concentrations during steady-state conditions
ArticleAbstract: Objectives: CYP2D6 drug-metabolising enzyme has been shown to be involved in fluoxetine metabolism iPalabras claves:CYP2C9, CYP2D6, Selective serotonin reuptake inhibitorsAutores:Adrián LLerena, Berecz R., Dorado P., González A.P., Penãs-Lledó E.M.Fuentes:scopusIncreased risk for major depression associated with the short allele of the serotonin transporter promoter region (5-HTTLPR-S) and the CYP2C9*3 allele
Conference ObjectAbstract: In the present study, we aimed to analyze the potential relevance of the polymorphism in the promotePalabras claves:5-HTTLPR, CYP2C9, genetic polymorphism, major depression, SerotoninAutores:Adrián LLerena, Cáceres M.C., Cobaleda J., Dorado P., González A.P., Penãs-Lledó E.M.Fuentes:scopusInfluence of genetic variants and antiepileptic drug co-treatment on lamotrigine plasma concentration in Mexican Mestizo patients with epilepsy
ArticleAbstract: Genetic and nongenetic factors may contribute to lamotrigine (LTG) plasma concentration variabilityPalabras claves:Autores:Adrián LLerena, Dorado P., Fricke-Galindo I., Jung-Cook H., López-López M., Martínez-Juárez I.E., Monroy-Jaramillo N., Ortega-Vázquez A., Penãs-Lledó E.M., Rojas-Tomé I.S.Fuentes:scopusElevated CYP2C19 expression is associated with depressive symptoms and hippocampal homeostasis impairment
ArticleAbstract: The polymorphic CYP2C19 enzyme metabolizes psychoactive compounds and is expressed in the adult livePalabras claves:Autores:Adrián LLerena, Baune B.T., Binder E.B., Carrillo-Roa T., Courtet P., Dannlowski U., de Quervain D.J., Ingelman-Sundberg M., Jukić M.M., Miksys S., Novalen M., Opel N., Papassotiropoulos A., Penãs-Lledó E.M., Renblom A., Sim S.C., Ström J., Tyndale R.F.Fuentes:scopus